(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization** International Bureau



(43) International Publication Date 8 January 2004 (08.01.2004)

PCT

(10) International Publication Number WO 2004/002413 A2

(51) International Patent Classification7:

A61K

(21) International Application Number:

PCT/US2003/020208

26 June 2003 (26.06.2003) (22) International Filing Date:

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/391,641

26 June 2002 (26.06.2002) US

- (71) Applicant (for all designated States except US): CHIL-DREN'S HOSPITAL MEDICAL CENTER [US/US]; 3333 Burnet Avenue, Cincinnati, OH 45229 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LANG, Richard, Anthony [AU/US]; 8917 Symmes Trace Court, Loveland, OH 45140 (US). LOBOV, Ivan, Borisovich [RU/US]; 601 Lowell Avenue, #17, Cincinnati, OH 85220 (US).


- (74) Agent: NESBITT, Daniel, F.; Hasse Guttag & Nesbitt LLC, 7577 Central Park Boulevard, Suite 316, Mason, OH 45040 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: IN VIVO ANGIOGENESIS ASSAY



(57) Abstract: A method for evaluating in vivo a test substance for angiogenesis modulation activity, including the steps of providing a rodent pup having a pupillary membrane system in a first eye, injecting transcorneally proximate to the pupillary membrane a test substance; and examining the pupillary membrane to determine whether new vascular tissue has grown. The method can also evaluate the ability of a test substance to regress existing vascular tissue, or to inhibit or prevent new vascular tissue, by injecting transcorneally a first substance that induces new vascular tissue growth, then injecting a test substance, and examining the pupillary membrane to determine whether new vascular tissue has grown. The assay can also be used to evaluate the effect of a small molecule on a property of a capillary vessel, and to evaluate a test substance on a problematic vascular condition.







For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.